Mamoru Fukuda
Papers
1
Total Citations
5
H-Index
1
About
Mamoru Fukuda is a leading urologic oncologist whose research centers on optimizing surgical and multimodal treatment strategies for high-risk prostate cancer. His most impactful work directly compares neoadjuvant chemohormonal therapy (NCHT) against extended pelvic lymph-node dissection (ePLND) in patients undergoing robot-assisted radical prostatectomy (RARP). In a landmark 2023 study involving 452 patients, Fukuda demonstrated that while NCHT prior to RARP may reduce the need for extensive lymph-node dissection, it carries distinct implications for postoperative complications and oncologic prognosis. This head-to-head analysis provides crucial evidence for surgeons deciding between systemic therapy intensification and aggressive local control. His findings help clarify the trade-offs in managing high-risk disease, where the choice between NCHT and ePLND can significantly impact both cancer outcomes and patient quality of life. With over 5 citations already for this key paper, Fukuda’s work is shaping contemporary debates in urologic oncology, offering data-driven guidance for personalizing treatment in the robotic surgery era. His contributions are especially valuable for clinicians seeking to balance the benefits of neoadjuvant therapy against the risks of extended nodal dissection.
Research Focus
Key Achievements
Top Papers
- 1